MedTrace Logo

Vaccine Against Atherosclerosis in Patients With Overweight Problems or Obesity

NCT03042741 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-04-16

No results posted yet for this study

Summary

Atherosclerosis vaccine, V6, has been through two small-scale Phase II open label clinical trials. It has shown significant improvement in lipid profile in patients with overweight or obesity

Conditions

Interventions

BIOLOGICAL

atherosclerosis vaccine

Atherosclerosis vaccine, V6, formulated as an oral pill made from from pooled antigens derived from adipose tissue

BIOLOGICAL

Placebo pills

Half of the patients will be randomly assigned to receive placebo pill

Sponsors & Collaborators

  • Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare

    collaborator OTHER_GOV

  • Immunitor LLC

    lead INDUSTRY

Principal Investigators

  • Allen Bain, PhD · Immunitor Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2019-12-18
Completion
2019-12-18

Countries

  • Mongolia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03042741 on ClinicalTrials.gov